Investment Summary

HBM Partners Exits Aculys Pharma

On October 15, 2025, Viatris invested in life science company Aculys Pharma from HBM Partners

Investment Highlights
  • This is Viatris’ 11th transaction in the Life Science sector.
  • This is Viatris’ 1st transaction in Japan.

Investment Summary

Date 2025-10-15
Target Aculys Pharma
Sector Life Science
Investor(s) Viatris
Sellers(s) HBM Partners
Deal Type Add-on Acquisition

Target

Aculys Pharma

Minato-ku, Japan
Aculys Pharma is a biopharmaceutical company focused on the development and commercialization of innovations in the fields of neurology and psychiatry. Aculys Pharma was founded in 2021 and is based in Minato-ku, Japan.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

Viatris

Canonsburg, Pennsylvania, United States

Category Company
Founded 1961
Sector Life Science
Employees32,000
Revenue 14.7B USD (2024)
DESCRIPTION

Viatris is a generic and specialty pharmaceutical company. Viatris offers the industry's broadest and highest quality product portfolios, a robust product pipeline, and a global commercial footprint through operations in more than 90 countries. Viatris was founded in 1961 and is based in Canonsburg, Pennsylvania.


DEAL STATS #
Overall 14 of 14
Sector: Life Science M&A 11 of 11
Type: Add-on Acquisition M&A Deals 5 of 5
Country: Japan M&A 1 of 1
Year: 2025 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-11-18 Viatris - Unit Dose Laboratories

Canonsburg, Pennsylvania, United States

Viatris' Unit Dose Laboratories provides unit-dose generic medicines to institutional and long-term care facilities. Viatris' Unit Dose Laboratories was founded in 1980 and is based in Canonsburg, Pennsylvania.

Sell -

Seller(S) 1

SELLER

HBM Partners

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 2001
PE ASSETS 2.1B USD
Size Large
Type Sector Focused
DESCRIPTION

HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.


DEAL STATS #
Overall 38 of 38
Sector: Life Science M&A 34 of 34
Type: Add-on Acquisition M&A Deals 7 of 7
Country: Japan M&A 1 of 1
Year: 2025 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-12-18 Sai Life

Hyderabad, India

Sai Life is an integrated provider of drug discovery, development, and manufacturing solutions for innovator pharmaceutical and biotechnology companies. The company’s ongoing commitment to quality, thorough approach, and state-of-the-art research and manufacturing facilities enable its highly skilled team of professionals to provide its clients with competitive advantages such as shorter time to market and risk minimization. Sai Life was founded in 1999 and is based in Hyderabad, Telangana.

Sell -